FRAX-based Intervention and Assessment Thresholds in Seven Latin American Countries

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2017 Dec 24

PMID 29273826

Citations 26

Authors

P Clark

E Denova-Gutierrez

C Zerbini

A Sanchez

O Messina

J J Jaller

C Campusano

C H Orces

G Riera

H Johansson

J A Kanis

Affiliations

Soon will be listed here.

Abstract

Introduction: Intervention thresholds are proposed using the Fracture Risk Assessment (FRAX) tool. We recommended their use to calculate the ten-year probability of fragility fracture (FF) in both, men and women with or without the inclusion of bone mineral density (BMD). The purpose of this study is to compute FRAX-based intervention and BMD assessment thresholds for seven Latin American countries in men and women ≥ 40 years.

Methods: The intervention threshold (IT) was set at a 10-year probability of a major osteoporotic fracture (MOF) equivalent to a woman with a prior FF and a body mass index (BMI) equal to 25.0 kg/m without BMD or other clinical risk factors. The lower assessment threshold was set at a 10-year probability of a MOF in women with BMI equal to 25.0 kg/m, no previous fracture and no clinical risk factors. The upper assessment threshold was set at 1.2 times the IT.

Results: For the seven LA countries, the age-specific IT varied from 1.5 to 27.5% in Argentina, 3.8 to 25.2% in Brazil, 1.6 up to 20.0% in Chile, 0.6 to 10.2% in Colombia, 0.9 up to 13.6% in Ecuador, 2.6 to 20.0% in Mexico, and 0.7 up to 22.0% in Venezuela at the age of 40 and 90 years, respectively.

Conclusions: In the LA countries, FRAX-based IT offers a substantial advance for the detection of men and women at high fracture risk, particularly in the elderly. The heterogeneity of IT between the LA countries indicates that country-specific FRAX models are appropriate rather than a global LA model.

Citing Articles

Conflating the Operational Definition of Osteoporosis with Intervention Thresholds.

Kanis J, Johansson H, Lorentzon M, Harvey N, McCloskey E Calcif Tissue Int. 2025; 116(1):22.

PMID: 39751843 DOI: 10.1007/s00223-024-01336-8.

A surrogate FRAX model for Nepal.

Johansson H, Pandey D, Lorentzon M, Harvey N, McCloskey E, Kanis J Arch Osteoporos. 2024; 19(1):115.

PMID: 39546110 PMC: 11568003. DOI: 10.1007/s11657-024-01474-4.

Clinical and demographic factors determining patient fracture risk decision point (FRDP): The improving risk communication in osteoporosis (RICO) project.

Sharma M, Beaudart C, Clark P, Fujiwara S, Adachi J, Papaioannou A Osteoporos Int. 2024; 36(1):71-80.

PMID: 39432087 PMC: 11706902. DOI: 10.1007/s00198-024-07264-5.

First year report of the IMSS Multicenter Hip Fracture Registry.

Duarte-Flores J, Cortez-Sarabia J, Sanchez-Garcia S, Medina-Chavez J, Castro-Flores S, Borboa-Garcia C Arch Osteoporos. 2024; 19(1):82.

PMID: 39223309 DOI: 10.1007/s11657-024-01444-w.

Race-specific FRAX models are evidence-based and support equitable care: a response to the ASBMR Task Force report on Clinical Algorithms for Fracture Risk.

Kanis J, Harvey N, Lorentzon M, Liu E, Schini M, Abrahamsen B Osteoporos Int. 2024; 35(9):1487-1496.

PMID: 38960982 DOI: 10.1007/s00198-024-07162-w.

References

Kanis J, Borgstrom F, Compston J, Dreinhofer K, Nolte E, Jonsson L . SCOPE: a scorecard for osteoporosis in Europe. Arch Osteoporos. 2013; 8:144. PMC: 3880480. DOI: 10.1007/s11657-013-0144-1. View

Kanis J, McCloskey E, Johansson H, Oden A, Leslie W . FRAX(®) with and without bone mineral density. Calcif Tissue Int. 2011; 90(1):1-13. DOI: 10.1007/s00223-011-9544-7. View

Kanis J, McCloskey E, Johansson H, Cooper C, Rizzoli R, Reginster J . European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2012; 24(1):23-57. PMC: 3587294. DOI: 10.1007/s00198-012-2074-y. View

Kanis J, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A . Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone. 2000; 27(5):585-90. DOI: 10.1016/s8756-3282(00)00381-1. View

Kanis J, Oden A, McCloskey E, Johansson H, Wahl D, Cooper C . A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int. 2012; 23(9):2239-56. PMC: 3421108. DOI: 10.1007/s00198-012-1964-3. View

Clark P, Cons-Molina F, Deleze M, Ragi S, Haddock L, Zanchetta J . The prevalence of radiographic vertebral fractures in Latin American countries: the Latin American Vertebral Osteoporosis Study (LAVOS). Osteoporos Int. 2008; 20(2):275-82. DOI: 10.1007/s00198-008-0657-4. View

Johansson H, Kanis J, Oden A, Compston J, McCloskey E . A comparison of case-finding strategies in the UK for the management of hip fractures. Osteoporos Int. 2012; 23(3):907-15. DOI: 10.1007/s00198-011-1864-y. View

Johansson H, Azizieh F, Al Ali N, Alessa T, Harvey N, McCloskey E . FRAX- vs. T-score-based intervention thresholds for osteoporosis. Osteoporos Int. 2017; 28(11):3099-3105. PMC: 5881885. DOI: 10.1007/s00198-017-4160-7. View

Compston J, Cooper A, Cooper C, Francis R, Kanis J, Marsh D . Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas. 2009; 62(2):105-8. DOI: 10.1016/j.maturitas.2008.11.022. View

10.

Kanis J, Harvey N, Cooper C, Johansson H, Oden A, McCloskey E . A systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos. 2016; 11(1):25. PMC: 4978487. DOI: 10.1007/s11657-016-0278-z. View

11.

Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J . Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations.... Arch Osteoporos. 2013; 8:136. PMC: 3880487. DOI: 10.1007/s11657-013-0136-1. View

12.

Qaseem A, Forciea M, Denberg T, Barry M, Cooke M, Fitterman N . Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians. Ann Intern Med. 2017; 166(11):818-839. DOI: 10.7326/M15-1361. View

13.

Johansson H, Oden A, Johnell O, Jonsson B, De Laet C, Oglesby A . Optimization of BMD measurements to identify high risk groups for treatment--a test analysis. J Bone Miner Res. 2004; 19(6):906-13. DOI: 10.1359/jbmr.2004.19.6.906. View

14.

Kanis J, McCloskey E, Johansson H, Strom O, Borgstrom F, Oden A . Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos Int. 2008; 19(10):1395-408. DOI: 10.1007/s00198-008-0712-1. View

15.

Kanis J, Oden A, Johnell O, Johansson H, De Laet C, Brown J . The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007; 18(8):1033-46. DOI: 10.1007/s00198-007-0343-y. View

16.

Johansson H, Clark P, Carlos F, Oden A, McCloskey E, Kanis J . Increasing age- and sex-specific rates of hip fracture in Mexico: a survey of the Mexican Institute of Social Security. Osteoporos Int. 2010; 22(8):2359-64. DOI: 10.1007/s00198-010-1475-z. View

17.

Rubin K, Friis-Holmberg T, Hermann A, Abrahamsen B, Brixen K . Risk assessment tools to identify women with increased risk of osteoporotic fracture: complexity or simplicity? A systematic review. J Bone Miner Res. 2013; 28(8):1701-17. DOI: 10.1002/jbmr.1956. View

18.

McCloskey E, Johansson H, Oden A, Austin M, Siris E, Wang A . Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res. 2012; 27(7):1480-6. DOI: 10.1002/jbmr.1606. View

19.

Johnell O, Kanis J, Oden A, Johansson H, De Laet C, Delmas P . Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005; 20(7):1185-94. DOI: 10.1359/JBMR.050304. View

20.

Kanis J, Adams J, Borgstrom F, Cooper C, Jonsson B, Preedy D . The cost-effectiveness of alendronate in the management of osteoporosis. Bone. 2007; 42(1):4-15. DOI: 10.1016/j.bone.2007.10.019. View